A new clinical trial is set to begin recruitment, aiming to improve medication adherence among adolescents and young adults living with cancer. Sponsored by leading medical institutions including Cincinnati Children’s Hospital, Seattle Children’s Hospital, Columbia University, and the National Cancer Institute (NCI), this study introduces a tailored intervention program designed to address the unique challenges experienced by this vulnerable population. While recruitment has yet to commence, the effort reflects a proactive step in making cancer care more effective and patient-centered.
What is the tailored intervention program?
The tailored program is a behavioral-based clinical intervention specifically designed to enhance medication adherence in adolescents and young adults diagnosed with cancer. By addressing individual patient needs and barriers to adherence, the program aims to improve treatment outcomes and reduce the potential for complications associated with missed or improper medication use.
Leveraging behavioral science principles, the program incorporates personalized strategies to support patients through their challenges. Its approach is particularly important in younger populations, who often face greater difficulty maintaining strict adherence during cancer treatment.
How does the feedback program differ?
In addition to the tailored intervention, the study includes a comparator group enrolled in a feedback program referred to as the ‘Uniform Standard of Care.’ This component provides behavioral feedback to patients regarding medication adherence but follows a standardized design rather than a personalized approach.
The inclusion of both groups allows researchers to measure the comparative effectiveness of personalized versus generalized adherence-promoting strategies.
Who is sponsoring this initiative?
This clinical study benefits from collaboration between several high-profile institutions. Leading the sponsorship effort are:
- Children’s Hospital Medical Center, Cincinnati
- National Cancer Institute (NCI)
- Seattle Children’s Hospital
- University of Kansas Medical Center
- Columbia University
These organizations bring expertise in pediatric and adolescent oncology, behavioral science, and clinical trials operations, ensuring the study is well-supported both scientifically and operationally.
Frequently Asked Questions
- Who can participate in this study? Adolescents and young adults diagnosed with cancer who meet eligibility criteria can enroll once recruitment begins.
- When does recruitment begin? As of October 2025, recruitment is listed as ‘Not yet recruiting.’
- How will outcomes be measured? The study will evaluate medication adherence rates and compare outcomes between the tailored intervention group and the feedback program group.
Implications for Patients and Care Teams
This clinical trial represents a significant opportunity to improve cancer care for younger patients by addressing critical adherence challenges. With its focus on personalized strategies and robust institutional support, the tailored approach has the potential to set a new standard in oncology treatment adherence.
Care teams, clinical researchers, and regulatory stakeholders are encouraged to monitor the progress of this study as it moves forward.
Disclaimer
This blog post is for informational purposes only and should not be interpreted as legal or clinical advice. Always consult regulatory requirements and clinical guidelines for project-specific decisions.
Study Announcement Link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07223463?term=medical+device